Avacta Group Plc (AVCTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avacta Group Plc (AVCTF) trades at $1.00 with AI Score 47/100 (Grade C). Avacta Group Plc is a clinical-stage biopharmaceutical company specializing in cancer therapies and diagnostics. Market cap: $468.40M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for AVCTF: AVCTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVCTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AVCTF: the 1 perspectives are evenly split.
How is this calculated? →Avacta Group Plc (AVCTF) Healthcare & Pipeline Overview
Avacta Group Plc (AVCTF) is a clinical-stage biopharmaceutical company that develops innovative cancer therapies and diagnostics using its proprietary Affimer and pre|CISION platforms, positioning itself as a key player in the biotechnology sector with a focus on advanced therapeutic solutions.
What Is the Investment Thesis for AVCTF?
Avacta Group Plc presents a compelling investment thesis driven by its innovative Affimer technology and strategic partnerships. The company is positioned to capitalize on the growing demand for advanced cancer therapies and diagnostics, with the global oncology therapeutics market projected to reach $200 billion by 2026. Avacta's collaborations with industry leaders like LG Chem Life Sciences and POINT Biopharma enhance its development capabilities and market reach. Furthermore, the ongoing clinical trials for its Affimer drug conjugate therapies and tumor-activated radiopharmaceuticals could yield significant milestones in the near term, potentially driving stock performance. However, investors should remain cautious of the high-risk profile associated with OTC stocks, particularly in the biotechnology sector, where regulatory approvals and funding requirements can impact operational stability. Monitoring these developments will be crucial for assessing Avacta's growth trajectory and financial health.
Based on FMP financials and quantitative analysis
AVCTF Key Highlights
- Market Cap of $468.40M reflects investor interest in innovative biopharmaceutical solutions.
- Profit Margin of -33961.1% indicates significant investment in R&D and operational costs.
- Gross Margin of -1031.9% highlights the early-stage nature of product development.
- Beta of 0.15 suggests low volatility compared to the broader market, appealing to risk-averse investors.
- No dividend yield, consistent with a focus on reinvestment for growth.
Who Are AVCTF's Competitors?
AVCTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVPT AvePoint, Inc. | $11.91 | +3.92% | $2.52B | 73 |
| EXEL Exelixis, Inc. | $55.36 | -0.88% | $13.91B | 99 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVCTF's Key Strengths?
- Innovative proprietary technology (Affimer) with broad applications.
- Strong partnerships with leading pharmaceutical and academic institutions.
- Experienced management team with a track record in biotechnology.
What Are AVCTF's Weaknesses?
- High operational costs associated with R&D and clinical trials.
- Negative profit margins indicating significant investment needs.
- Limited product portfolio at the current stage of development.
What Could Drive AVCTF Stock Higher?
- Clinical trial results for Affimer drug conjugate therapies expected in Q4 2026.
- Development of tumor-activated radiopharmaceuticals in collaboration with POINT Biopharma.
- Expansion of AffiDX SARS-CoV-2 testing capabilities to new markets in 2026.
- Research collaboration with Tufts University School of Medicine for innovative therapies.
- Potential licensing agreements for new Affimer products in 2026.
What Are the Key Risks for AVCTF?
- Financial-distress signal — its Altman Z-Score of -6.73 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles may delay product approvals and market entry.
- High operational costs impacting profitability and cash flow.
- Competitive pressures from established biotechnology firms.
- Market volatility affecting funding and investment opportunities.
- Dependence on successful clinical trial outcomes for future growth.
What Are the Growth Opportunities for AVCTF?
- Growth opportunity 1: Avacta's collaboration with LG Chem Life Sciences to develop innovative cancer therapies is a significant growth driver. The global cancer therapeutics market is expected to grow at a CAGR of 10.7%, reaching $200 billion by 2026. This partnership enhances Avacta's capabilities in drug development, potentially leading to new treatments that address unmet medical needs.
- Growth opportunity 2: The ongoing development of Affimer drug conjugate therapies in partnership with Tufts University School of Medicine represents a strategic avenue for growth. As the demand for targeted cancer therapies increases, Avacta's innovative approach could capture market share in the expanding oncology sector, projected to grow substantially in the coming years.
- Growth opportunity 3: Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen tests have positioned the company as a key player in diagnostics during the pandemic. The global diagnostics market is anticipated to grow at a CAGR of 6.7%, reaching $70 billion by 2027. Continued innovation in diagnostic solutions can drive revenue growth and enhance market presence.
- Growth opportunity 4: The licensing agreement with POINT Biopharma for the development of tumor-activated radiopharmaceuticals opens new avenues in the oncology landscape. As the market for radiopharmaceuticals expands, Avacta's unique approach could lead to significant advancements and revenue generation in this niche segment.
- Growth opportunity 5: The partnership with AffyXell to develop engineered mesenchymal stem cells for autoimmune diseases presents a diversification opportunity for Avacta. The global market for stem cell therapies is projected to reach $200 billion by 2030, providing Avacta with a chance to expand its therapeutic portfolio and address a broader range of health conditions.
What Opportunities Does AVCTF Have?
- Growing global demand for cancer therapies and diagnostics.
- Potential for expansion into new therapeutic areas and markets.
- Increasing interest in personalized medicine and targeted therapies.
What Threats Does AVCTF Face?
- Intense competition from established biotechnology firms.
- Regulatory challenges in obtaining approvals for new therapies.
- Market volatility affecting funding and investment in biotech.
What Are AVCTF's Competitive Advantages?
- Proprietary Affimer technology provides a competitive edge in biopharmaceuticals.
- Strong partnerships with leading organizations enhance development capabilities.
- Focus on innovative cancer therapies addresses significant market needs.
- Established presence in multiple geographic markets increases resilience.
- Expertise in both diagnostics and therapeutics offers a diversified product portfolio.
What Does AVCTF Do?
Founded in 2003 and headquartered in Wetherby, United Kingdom, Avacta Group Plc is a clinical-stage biopharmaceutical company that specializes in the development of cancer therapies and diagnostics. The company operates primarily through two segments: Diagnostics and Therapeutics. Avacta's proprietary Affimer technology offers engineered proteins that serve as versatile alternatives to traditional antibodies, enabling the creation of custom Affimer proteins for various customer products and in-house diagnostic assays. Among its notable products is the AffiDX SARS-CoV-2 lateral flow rapid antigen test, which highlights the company's capability to respond to urgent health challenges. Avacta has established several strategic collaborations, including a research partnership focused on pre|CISION technology, which targets drug delivery to tumors via a substrate sensitive to fibroblast activation protein alpha. Additionally, the company collaborates with LG Chem Life Sciences for drug development, and has partnered with Tufts University School of Medicine to develop Affimer drug conjugate therapies. Avacta's licensing agreement with POINT Biopharma Inc. aims to develop tumor-activated radiopharmaceuticals, while its partnership with AffyXell focuses on engineered mesenchymal stem cells for treating autoimmune diseases. Through these initiatives, Avacta aims to leverage its innovative platforms to create impactful cancer therapies and diagnostic solutions, solidifying its position in the rapidly evolving biotechnology landscape.
What Products and Services Does AVCTF Offer?
- Develop cancer therapies using proprietary Affimer technology.
- Create diagnostic assays for various diseases, including COVID-19.
- Engage in research collaborations to enhance product development.
- License technologies for the development of advanced therapeutics.
- Partner with academic institutions for innovative research.
- Focus on creating engineered proteins as alternatives to antibodies.
How Does AVCTF Make Money?
- Generate revenue through the sale of diagnostic assays and tests.
- Engage in partnerships and collaborations for drug development.
- License proprietary technologies to third parties for commercialization.
- Develop custom Affimer proteins for clients in various industries.
- Invest in R&D to create innovative therapeutic solutions.
What Industry Does AVCTF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in personalized medicine and innovative therapeutic solutions. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with oncology being a significant contributor to this growth. Avacta Group Plc operates within this dynamic landscape, focusing on cancer therapies and diagnostics, which are critical areas of focus for healthcare providers and investors alike. The competitive landscape includes established players and emerging biotech firms, making innovation and strategic partnerships essential for success. Avacta's proprietary platforms position it well to compete effectively in this evolving market.
Who Are AVCTF's Key Customers?
- Healthcare providers seeking advanced diagnostic solutions.
- Pharmaceutical companies interested in innovative drug development.
- Academic institutions collaborating on research projects.
- Biotechnology firms licensing proprietary technologies.
- Government agencies requiring rapid testing solutions.
Company Profile
Avacta Group Plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wetherby, GB. The company is led by CEO Christina Marie Coughlin. AVCTF has traded publicly since 2020.
Avacta Group Plc Financial Trajectory
Avacta Group Plc (AVCTF) reported $57K in revenue for Q4 2025, reflecting 1.8% growth compared to the prior quarter. The company recorded a net loss of $21.3M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.
How Avacta Group Plc Is Valued
Avacta Group Plc carries a market capitalization of $468.40M, placing it in the small-cap category. Relative to its peer group, AVCTF's quantitative score of 47/100 is below the peer average of 81/100.
Key Financial Metrics
Its free cash flow yield is -8.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.89 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Avacta Group Plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.73 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Avacta Group Plc revenue of about $31.0M for fiscal 2026, with EPS near $-0.07.
AVCTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative proprietary technology (Affimer) with broad applications.
- Strong partnerships with leading pharmaceutical and academic institutions.
- Experienced management team with a track record in biotechnology.
- Upcoming: Clinical trial results for Affimer drug conjugate therapies expected in Q4 2026.
Bear Case
- High operational costs associated with R&D and clinical trials.
- Negative profit margins indicating significant investment needs.
- Limited product portfolio at the current stage of development.
- Potential: Regulatory hurdles may delay product approvals and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $56,990 | -$21M | -$0.05 |
| Q2 2025 | $56,000 | -$18M | -$0.04 |
| Q2 2024 | $11M | -$12M | -$0.04 |
Based on FMP financials and quantitative analysis
AVCTF Latest News
-
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
globenewswire.com · Jun 1, 2026
-
Avacta Group Plc (AVCTF) Q4 2025 Earnings Call Transcript
seekingalpha.com · May 25, 2026
AVCTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVCTF.
Price Targets
Wall Street price target analysis for AVCTF.
AVCTF MoonshotScore
What does this score mean?
The MoonshotScore rates AVCTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christina Marie Coughlin
CEO
Christina Marie Coughlin has extensive experience in the biotechnology sector, holding key leadership positions in various biopharmaceutical companies. She has a strong background in drug development and commercialization, with a focus on oncology and diagnostics. Christina holds a Ph.D. in Biochemistry and has contributed to numerous successful product launches throughout her career.
Track Record: Under Christina's leadership, Avacta Group Plc has made significant strides in advancing its proprietary technology and expanding its product pipeline. Her strategic decisions have led to key partnerships and collaborations that enhance the company's development capabilities and market presence.
AVCTF OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and higher volatility, making them riskier investments. Companies in this tier often have less stringent reporting requirements, which can impact transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Higher volatility associated with OTC stocks compared to major exchanges.
- Limited visibility and transparency due to less stringent reporting requirements.
- Potential for lower trading volumes, affecting liquidity and price stability.
- Regulatory scrutiny can impact operational capabilities and market access.
- Increased risk of market manipulation due to lower oversight.
- Verify the company's financial health through available reports.
- Assess the credibility of partnerships and collaborations.
- Monitor clinical trial progress and regulatory developments.
- Evaluate the competitive landscape and market positioning.
- Review management's track record and strategic vision.
- Established partnerships with reputable organizations in the biotechnology sector.
- Transparency in financial reporting and operational updates.
- Presence in multiple geographic markets, indicating a broad reach.
Common Questions About AVCTF (Healthcare)
What does Avacta Group Plc do?
Avacta Group Plc is a clinical-stage biopharmaceutical company that develops cancer therapies and diagnostics. Utilizing its proprietary Affimer technology, the company creates innovative solutions for oncology and diagnostic applications, including custom proteins and rapid antigen tests for diseases such as COVID-19.
What are the main risks for AVCTF?
Avacta Group Plc faces several risks, including regulatory hurdles that may delay product approvals, high operational costs that impact profitability, and competitive pressures from established biotechnology firms. Additionally, market volatility can affect funding opportunities, and the company's growth is dependent on the success of its clinical trials.
What revenue streams does Avacta Group Plc have in healthcare?
Avacta Group Plc generates revenue through multiple streams, including the sale of diagnostic assays and tests, partnerships for drug development, and licensing agreements for proprietary technologies. The company also develops custom Affimer proteins for clients across various industries, enhancing its revenue diversification.
What are the key factors to evaluate for AVCTF?
Avacta Group Plc (AVCTF) holds an AI score of 47/100 (low). Not financial advice.
How frequently does AVCTF data refresh on this page?
AVCTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AVCTF's recent stock price performance?
Avacta Group Plc (AVCTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technology (Affimer) with broad applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AVCTF overvalued or undervalued right now?
Valuing Avacta Group Plc (AVCTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AVCTF?
Before investing in Avacta Group Plc (AVCTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The financial data is based on the latest available information and may be subject to change.